Top-Rated StocksTop-RatedNASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $51.61 +1.52 (+3.03%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$52.40 +0.79 (+1.52%) As of 06/20/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Disc Medicine Stock (NASDAQ:IRON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Disc Medicine alerts:Sign Up Key Stats Today's Range$49.85▼$51.8450-Day Range$40.27▼$53.7152-Week Range$30.82▼$68.73Volume413,971 shsAverage Volume345,690 shsMarket Capitalization$1.79 billionP/E RatioN/ADividend YieldN/APrice Target$96.70Consensus RatingBuy Company OverviewDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Read More… Disc Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreIRON MarketRank™: Disc Medicine scored higher than 44% of companies evaluated by MarketBeat, and ranked 1795th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDisc Medicine has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDisc Medicine has only been the subject of 4 research reports in the past 90 days.Read more about Disc Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -13.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -13.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 3.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Disc Medicine's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.71% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Disc Medicine has recently decreased by 4.02%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.71% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Disc Medicine has recently decreased by 4.02%, indicating that investor sentiment is improving. News and Social Media2.1 / 5News Sentiment0.77 News SentimentDisc Medicine has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Disc Medicine this week, compared to 6 articles on an average week.Search InterestOnly 3 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,544,871.00 in company stock.Percentage Held by InsidersOnly 4.24% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address IRON Stock News HeadlinesJean M. Franchi Sells 2,000 Shares of Disc Medicine, Inc. (NASDAQ:IRON) StockJune 19 at 7:48 AM | insidertrades.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 2,996 Shares of StockJune 10, 2025 | insidertrades.comAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. June 21, 2025 | Timothy Sykes (Ad)Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 6,677 Shares of StockMay 23, 2025 | insidertrades.comLifesci Capital Forecasts Disc Medicine FY2025 EarningsJune 20 at 1:33 AM | americanbankingnews.comLifesci Capital Predicts Disc Medicine Q2 EarningsJune 19 at 1:55 AM | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Disc Medicine (NASDAQ:IRON)June 18 at 2:17 AM | americanbankingnews.comDisc Medicine (NASDAQ:IRON) Earns Outperform Rating from WedbushJune 17, 2025 | americanbankingnews.comSee More Headlines IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $63.40 on January 1st, 2025. Since then, IRON shares have decreased by 18.6% and is now trading at $51.61. View the best growth stocks for 2025 here. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) announced its quarterly earnings data on Wednesday, May, 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by $0.03. Who are Disc Medicine's major shareholders? Top institutional shareholders of Disc Medicine include Atlas Venture Life Science Advisors LLC (6.90%), Wellington Management Group LLP (6.78%), RA Capital Management L.P. (4.56%) and Price T Rowe Associates Inc. MD (3.93%). Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, Kevin Bitterman, Mona Ashiya, John D Quisel, Pamela Stephenson, Jean M Franchi, William Jacob Savage, Jonathan Yen-Wen Yu, Rahul Khara, Brian Richard Macdonald, Joanne Bryce and William Richard White. View institutional ownership trends. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Disc Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings5/07/2025Today6/21/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRON CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$96.70 High Stock Price Target$132.00 Low Stock Price Target$75.00 Potential Upside/Downside+87.4%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-22.61% Return on Assets-21.07% Debt Debt-to-Equity Ratio0.04 Current Ratio37.65 Quick Ratio37.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.85 per share Price / Book3.48Miscellaneous Outstanding Shares34,630,000Free Float33,166,000Market Cap$1.79 billion OptionableNot Optionable Beta0.73 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:IRON) was last updated on 6/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.